To evaluate the effectiveness of Gamma Knife radiosurgery (GKRS) as the primary and only therapy for the treatment of cavernous sinus hemangiomas (CSH) and to report the tumor volume dynamics, course of symptoms, and complications after stereotactic radiosurgery.
█ INTRODUCTION
C avernous sinus hemangiomas (CSH) are rare, benign, and intracranial vascular neoplasms that account for approximately 3% of all cavernous sinus tumors (9) . CSH differ from cavernous hemangiomas (cavernomas) as they are extra-axial, vascular, and produce symptoms due to tumor progression and mass effect (9, 10) . These lesions predominantly occur in middle-aged women and may cause neurological symptoms such as headaches, retro-orbital pain, and progressive ocular movement disorders (10, 11) .
Complete microsurgical removal of CSH is curative, but is associated with some well-known risks. Due to the hypervascular nature and location of these tumors, microsurgery may be complicated by severe intra-operative hemorrhage and post-operative cranial nerve deficits (9, 11, 12, 14, 16, 24) .
Over the last two decades, some promising results have been reported in the treatment of CSH. Very low morbidity and almost no mortality were reported when stereotactic radiosurgery (SRS) was used to treat CSH. While previous CSH treatment studies reported the status of post-operative residual tumors, today most centers using SRS as the primary and often the sole treatment modality report favorable outcomes (1) (2) (3) (5) (6) (7) 13, 15, 17, 21, 22) .
The aim of the current study is to evaluate the use of Gamma Knife radiosurgery (GKRS) as the primary treatment modality for CSH based on pre-and post-operative clinical and radiological findings.
█ MATERIAL and METHODS
Between 2010 and 2018, a total of 10 CSH patients were treated with GKRS at Baskent University Adana Dr. Turgut Noyan Medical Center Gamma Knife Unit. Data on the demographic, clinical, radiological, and radiosurgical characteristics of the patients and their tumors were obtained from patients' charts retrospectively. Tumor volumes were evaluated using magnetic resonance (MR) images before and after the treatment using follow-up images acquired 2, 6 and 12 months post-treatment, and yearly thereafter.
Tumors that demonstrated low-or iso-intensity on T1-weighted sequences, well-defined marked hyper-intensity on T2-weighted sequences, and fluid-attenuated inversion recovery (FLAIR) images were identified as CSH. In contrast, meningiomas and schwannomas show low-or iso-intensity on T2-weighted sequences and FLAIR images. After contrast agent administration, CSH demonstrate significant and homogenous enhancement on the T1-weighted post-contrast images. In addition, CSH typically lack a dural tail ( Figure 1A -C). Due to these unique identifying features, brain magnetic resonance imaging was the primary tool used for CSH diagnosis in our patients. There was no history of microsurgical treatment or open biopsy in our patients.
Radiosurgical Technique
Leksell G stereotactic frame (Elekta, Sweden) was applied to the patient's head under local anesthesia and brain MR images were obtained. The Leksell Gamma Plan 10.1 software was used for dose planning. The aim of dose planning was to cover the whole lesion with multi-isocenters while adjusting the radiation dose for critical structures such as the optic apparatus (below 8 Gy) and the brainstem (below 12 Gy). Leksell Gamma Knife 4-C was used for the treatment.
Volumetric Evaluation Technique
Prior to the treatment, tumor volumes were measured and noted using the Leksell Gamma Plan 10.1 software. Tumor volumes after the treatment were calculated as the sum of the areas contoured on each slice multiplied by slice thickness. Previous volumetric studies using the trapezoidal rule formula demonstrate that with accurate delineation on at least five slices, the calculated volume would have an expected error rate of 10% or less (18) .
All volumetric measurements were made on enhanced T1-weighted MR images.
The volume response was classified according to the Wang grading system as follows (22):
Grade 1-Good response: Shrinkage of more than 50% of the tumor volume.
Grade 2-Partial response: Shrinkage of more than 25% and less than 50% of tumor volume.
Grade 3-No change: Less than 25% shrinkage of the tumor volume.
█ RESULTS
The study included five females and five males with a median age of 49 years (range 15-68 years). CSH was located on the right side in three patients and to the left in seven patients. Prior to treatment, all patients complained of headache and retro-orbital pain. In addition, six patients complained of diplopia and abducens nerve paralysis during the initial neurological examination (Table I ). The median tumor volume was 4.98 cm 3 (range 2-10.9 cm 3 ) and median margin dose was 14.2 Gy (range 13-16 Gy).
Clinical Outcome
The median follow-up period of 10 CSH patients treated with GKRS was 42 months (range12-85 months). Following treatment, all patients declared some improvement in their previous headache and retro-orbital pain, while six patients reported complete resolution of headache. Within six months of treatment, abducens nerve paralysis and accompanying diplopia recovered fully in all six patients. No adverse events related to radiosurgical treatment were recorded.
Tumor Response
After GKRS treatment, marked tumor regression was observed within the first 6 months of treatment. At the first-year followup, treated tumors decreased in volume by at least 74%. Furthermore, volume reduction continued at the 24-and 36-month evaluations. Tumors less than 6 cm 3 in volume nearly disappeared at 24 months. After a median follow-up period of 42 months, tumor volumes reduced more than 90.2% on average (Table II) . There was no tumor progression or regrowth in our patients (Figures 2, 3 ).
█ DISCUSSION
Microsurgical removal of CSH is challenging because of well-known risks associated with cavernous sinus surgery including severe operative bleeding and cranial nerve deficits. Moreover, it was recently reported that total microsurgical removal could only be managed in 44%-55% of patients (8) .
Previously, treating inoperable and residual CSH patients with conventional radiotherapy achieved satisfactory tumor shrinkage. Subsequently, SRS was used as a more conformal treatment modality given its ability to preserve critical structures such as the optic apparatus, brain stem, and pituitary gland. In 1994, Iwai et al. reported the first successful treatment of a residual CSH with Gamma Knife (4). However, most early reports about CSH treatment with SRS were for residual tumors with a small sample size.
In 2012, Wang et al. presented a systematic review and metaanalysis on radiosurgical treatment of CSH that included 59 patients. After a mean follow-up of 49.2 months, they reported remarkable shrinkage in 67.8% of patients, partial response in 25.4%, and no change in 6.8% of the patients. Additionally, they reported only one case of trigeminal nerve disturbance as a side effect (24) .
In 2015, Tang et al. published their case series that included 53 CSH patients treated with the Gamma Knife. They reported 100% tumor control rate with over 80% reduction in tumor volume in 55% of patients after a 24-month radiological follow-up period. Thirty three of the 53 patients demonstrated significant improvements in their clinical status, although two patients showed temporary clinical deterioration (20) . Recently, Lee et al. reported a multi-center retrospective study that included 31 CSH cases. Twenty of these patients underwent Gamma Knife as the primary treatment. They demonstrated more than 50% reduction in tumor volume within 6 months in all patients. Also, no delayed tumor regrowth, new cranial neuropathy or radiation-induced adverse effects were observed (7).
CSH show low-or iso-intensity on T1-weighted images and well-defined marked hyper-intensity (as bright as the cerebrospinal fluid signal) on T2-weighted and FLAIR images. Furthermore, they show strong homogenous enhancement on T1-weighted images after injection of the contrast agent gadolinium. Typically, CSH lack a dural tail. Therefore, it is possible to differentiate CSH from pituitary adenomas, meningiomas, and schwannomas based on these unique radiological features ( Figure 1A-C) . Such characteristic radiological findings avert the need for an open biopsy for exact diagnosis of CSH (1). This is an advantage because, similar to microsurgical removal, open biopsy may also result in significant morbidity (5, 10, 19, 23) .
Since CSH has satisfactorily unique radiological features that aid its diagnosis, treating these tumors with radiosurgery as the primary and only therapy seems rational. The aim of the current study was to evaluate the effectiveness of GKRS as the primary and only therapy for the treatment of CSH and to report the tumor volume dynamics, course of symptoms, and complications after treatment. Moreover, abducens nerve paralysis recovered in all patients, and severity of headache and retro-orbital pain was reduced or eliminated within the first six months. No radiation-induced neuropathies or other side effects were observed.
Our findings are in agreement with other recently published studies in the literature. Small sample size, stemming from the rarity of this disease, is the most important limitation of our retrospective study. Prospective, multi-center studies with large sample sizes are needed in the future.
In our case series, GKRS resulted in a tumor volume response of grade 1 on the Wang grading system after a median follow-up period of 42 months. Our study suggests that the beneficial effects of GKRS may mainly occur within the first 6 months of treatment. Indeed, tumor shrinkage began as early as 2 months after treatment, and at least 74% of tumor volume reduction was achieved during the first year. Average tumor reduction at first-year follow-up was 90.2%. After the first year, the tumor shrinkage continued at a slower pace. 1a, 2a, 3a) show a prominent tumor in the right or left cavernous sinus. Satisfying tumor shrinkage was observed on MR images acquired 6 months (1b, 2b, 3b) and 12 months (1c, 2c, 3c) after the treatment.
